← board
SDZNY
distress 0/10 · well-funded / low risk$78.53+0%today-16% from 52w high
Revenue
$11157M
Liquidity
$1739M
Runway
—
Shares 1y
—
Price & events
+0.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.5%
1W
-9.9%
1M
-3.6%
3M
-2.1%
6M
+32.7%
1Y
+108.5%
2Y
—
5Y
+209.8%
All
Overview
- Volume
- 29
- 52 Week Range
- $55.91 – $93.35
- Float Shares
- 414.32M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.36%
- RVOL
- 0.00x
- Beta
- 0.50
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $91 (+16% upside) · 2 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.